These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7302695)

  • 41. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin.
    Tsang RC; Roginsky MS; Mellies MJ; Glueck CJ
    Pediatr Res; 1978 Oct; 12(10):980-2. PubMed ID: 724301
    [No Abstract]   [Full Text] [Related]  

  • 42. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
    Geiss HC; Schwandt P; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2002 Jun; 110(4):182-7. PubMed ID: 12058342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients.
    Gundersen K; Cooper EE; Ruoff G; Nikolai T; Assenzo JR
    Atherosclerosis; 1976; 25(2-3):303-10. PubMed ID: 795441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.
    Lind S; Rudling M; Ericsson S; Olivecrona H; Eriksson M; Borgström B; Eggertsen G; Berglund L; Angelin B
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):349-56. PubMed ID: 14656733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bile acid sequestrants and cholesterol.
    Schon P
    N Z Med J; 1990 Apr; 103(887):163. PubMed ID: 2111529
    [No Abstract]   [Full Text] [Related]  

  • 46. Low dose colestipol in adolescents with familial hypercholesterolaemia.
    Tonstad S; Sivertsen M; Aksnes L; Ose L
    Arch Dis Child; 1996 Feb; 74(2):157-60. PubMed ID: 8660081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Long-term therapy of familial hypercholesterolemia in young patients with colestipol: availability of minerals and vitamins].
    Schlierf G; Vogel G; Kohlmeier M; Vuilleumier JP; Hüppe R; Schmidt-Gayk H
    Klin Wochenschr; 1985 Sep; 63(17):802-6. PubMed ID: 3932748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hypercholesterolemia. Can it retard atherogenesis?
    Untereker WJ
    Int J Cardiol; 1982; 2(1):57-9. PubMed ID: 7129690
    [No Abstract]   [Full Text] [Related]  

  • 49. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
    Bilheimer DW; Grundy SM; Brown MS; Goldstein JL
    Atheroscler Suppl; 2004 Oct; 5(3):61-5. PubMed ID: 15531277
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute digoxin overdosage: potential role of colestipol therapy.
    Hamburger S; Covinsky JO; Styczynski M; Uhrig L
    J Kans Med Soc; 1980 Oct; 81(10):464. PubMed ID: 7229494
    [No Abstract]   [Full Text] [Related]  

  • 51. [Familial hypercholesterolemia. Study of a family].
    Ahumada-Ayala M; Núñez-Pulache A; Lozano-Castañeda O; Rull JA; Valles VE; Wong B
    Rev Invest Clin; 1984; 36(3):269-75. PubMed ID: 6515160
    [No Abstract]   [Full Text] [Related]  

  • 52. [Experiences with a new cholesterolemia-lowering resin, Colestipol (U-26, 597 A. Upjohn)].
    Muls E; Lemmens P
    Acta Clin Belg; 1975; 30(5):409-14. PubMed ID: 1221747
    [No Abstract]   [Full Text] [Related]  

  • 53. Cholesterol, colestipol and coronary heart disease.
    Stone NJ
    J Chronic Dis; 1978 Jan; 31(1):1-3. PubMed ID: 346595
    [No Abstract]   [Full Text] [Related]  

  • 54. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 55. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, tolerance, and safety of colestipol HCL as a hypocholesterolemic agent in hyperlipidemic patients with studies of its effect on gastrointestinal absorption.
    Faruqui AM; Thurmond MS; Wenger J; Wenger NK
    J Pak Med Assoc; 1981 Nov; 31(11):241-5. PubMed ID: 6802993
    [No Abstract]   [Full Text] [Related]  

  • 57. Colestipol-niacin therapy and coronary atherosclerosis.
    JAMA; 1987 Nov; 258(19):2694-6. PubMed ID: 3669238
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
    Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W
    Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
    Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
    van Wissen S; Smilde TJ; Trip MD; Stalenhoef AF; Kastelein JJ
    Am J Cardiol; 2005 Jan; 95(2):264-6. PubMed ID: 15642565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.